Clover Biopharmaceuticals, Ltd. (2197.HK)

0.400 +0.005 (+1.27%) At close: 04:08PM HKT

Clover Biopharmaceuticals, Ltd.

No. 758 West Nanjing Road
Room 1901 Jing'an District
Shanghai
China

https://www.cloverbiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 387

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Peng Liang Ph.D.	Founder, Chief Scientific Officer & Chairman of the Board	3.08M	N/A	1961
Mr. Joshua G. Liang	CEO & Executive Director	4.82M	N/A	1993
Dr. Yang Li Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Ms. Htay Htay Han MBBS	Chief Medical Officer of Vaccine	N/A	N/A	1969
Dr. Berry Michael Ph.D.	Chief Technical Operation Officer	N/A	N/A	1966
Ms. Abigail Bracha Ph.D.	Senior Vice President of Corporate Strategy & Business Development	N/A	N/A	N/A
Ms. Tracy Wang	Senior Vice President of Head of Regulatory Affairs, China	N/A	N/A	N/A
Dr. Nicholas Jackson M.Sc., Ph.D.	President of Global Research & Development	N/A	N/A	1971
Mr. LiongHo Chua	President of Greater China	N/A	N/A	1964
Dr. Igor Smolenov M.D., Ph.D.	Executive Vice President of Global Clinical Development Vaccines	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China. Its product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia; and SCB-313, an oncology product candidate for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis. The company is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, it provides consulting services and sells biopharmaceutical drugs. The company was founded in 2007 and is headquartered in Shanghai, the People's Republic of China.

Corporate governance

Clover Biopharmaceuticals, Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.